Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 safety and feeding tolerance study in extremely preterm and growth-restricted preterm infants
NL-OMON53321Phase 2Not yet recruiting
- Sponsor
- Elgan Pharma
- Start
- Aug 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in preterm birth comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Safety of ELGN-2112 compared with placebo. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
elgn-gi
03
Conditions
preterm birth
Beyond the preview
Go deeper on NL-OMON53321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53321.